Lawmakers on the House Energy and Commerce Committee have called for clarification from the CDC regarding its funding of a hepatitis B vaccine trial in Guinea-Bissau, raising concerns over the study’s ethical and operational standards. The agency provided $1.6 million in funding to Danish researchers for the research, which has sparked debate over transparency and accountability in public health initiatives. Critics question whether proper safeguards were in place given the trial’s location and the potential risks involved. The push for answers underscores growing scrutiny over how federal health dollars are allocated in international medical research.
Top Democrats on the House Energy and Commerce Committee demanded answers Thursday from the Centers for Disease Control and Prevention (CDC) about the agency’s funding of a controversial hepatitis B clinical trial in Guinea-Bissau. The CDC awarded $1.6 million last year to Danish researchers to conduct the study in Guinea-Bissau, a small country in West...
